Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on diphtheria infections in Scotland for the period July to September 2024 (week 39).

Infections in Scotland

Diphtheria

HTML

ECOSS (Electronic Communication of Surveillance in Scotland).

4 October 2024

3 December 2024

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data in the most recent quarterly updates supersedes data reported in previous reports.

This publication has no revisions.

Diphtheria is an acute bacterial infection affecting the upper respiratory tract or the skin, caused by the diphtheria toxin produced by toxigenic strains of Corynebacterium.

The most common symptoms of diphtheria affecting the upper respiratory tract are membranous pharyngitis with fever, lymphadenopathy and upper respiratory tract soft tissue swelling ‘bull neck’ potentially leading to life-threatening airway obstruction.

Cutaneous diphtheria may cause pus-filled blisters on legs, hands and feet and ulceration of the skin.

In unvaccinated or partially vaccinated individuals, systemic absorption of the toxin can lead to late complications such as cardiac and neurological conditions and sometimes death.

Immunisation against diphtheria is offered to babies and children as part of the routine childhood immunisation schedule.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of Diphtheria and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

All data returned from ECOSS and the enhanced surveillance database are used for analysis

Scottish data is regularly compared to UKHSA diphtheria data and information. 

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of laboratory-confirmed toxigenic strains of Corynebacterium.

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on laboratory-confirmed cases of invasive Haemophilus influenzae infections reported in Scotland for the period July to September 2024 (week 39)

Infections in Scotland

Haemophilus influenzae

HTML

ECOSS (Electronic Communication of Surveillance in Scotland).

Enhanced surveillance database for all paediatric (younger than 5 years of age) of any type, and all invasive type b.

National Records of Scotland for mid-year population estimates (used for incidence calculations).

15 October 2024

Agreed date to allow quality assurance checks.

3 December 2024

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 1988 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

Incidence rates in Table 2b in ‘Vaccine-preventable disease summary’ will differ slightly from previous publications for 2023 as these have been updated using the NRS mid-year population estimates for 2023.

Haemophilus influenzae (H. influenzae) are bacteria commonly carried in the respiratory tract which can cause serious invasive disease, especially in young children.

Invasive disease is usually caused by the encapsulated strains, specifically, six capsular serotypes (a to f) of which type b (Hib) was the most common, until the introduction of the vaccine.

The most common presentations of invasive H. influenzae infection are meningitis, septicaemia and acute respiratory infections.

Vaccination for Hib is part of the routine childhood immunisations schedule.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of invasive Haemophilus influenzae and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

All data returned from ECOSS and the enhanced surveillance database are used for analysis

Scottish data is regularly compared to UKHSA Haemophilus influenzae data and information. 

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of new H. Influenzae isolates from sterile sites.

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on laboratory-confirmed and epidemiologically linked cases of measles reported in Scotland from July to September 2024 (week 39)

Infections in Scotland

Measles infection

HTML

ECOSS (Electronic Communication of Surveillance in Scotland), Colindale/UKHSA, Enhanced surveillance database.

National Records of Scotland for mid-year population estimates (used for incidence calculations).

1 November 2024.

Agreed date to allow quality assurance checks.

3 December 2024

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 1988 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

Incidence rates in Table 2b in ‘Vaccine-preventable disease summary’ will differ slightly from previous publications for 2023 as these have been updated using the NRS mid-year population estimates for 2023.

Measles is a rash illness resulting from infection with the measles virus.

It can affect people of all ages but infants less than one year of age and those who are immunocompromised are at increased risk of complications and death.

It's one of the most communicable diseases with one case having the potential to infect another 12 to 18 individuals through airborne transmission and respiratory droplets in susceptible populations.

New cases of measles are identified by laboratory testing based on positive PCR or IgM serology.

MMR is the combined vaccine that protects against measles, mumps and rubella and is the most effective strategy for preventing the transmission of measles.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of measles and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

All data returned from ECOSS and the enhanced surveillance database are used for analysis

Scottish data is regularly compared to UKHSA measles data and information.

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of new measles infections

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on the clinical and laboratory confirmed cases of meningococcal disease reported in Scotland for the period July to September 2024 (week 39).

Infections in Scotland

Meningococcal Disease

HTML

ECOSS (Electronic Communication of Surveillance in Scotland).

Meningococcal Invasive Disease Augments Surveillance (MIDAS).

National Records of Scotland for mid-year population estimates (used for incidence calculations).

15 October 2024

Agreed date to allow quality assurance checks.

3 December 2024

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 2001 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

Incidence rates in Table 2b in ‘Vaccine-preventable disease summary’ will differ slightly from previous publications for 2023 as these have been updated using the NRS mid-year population estimates for 2023.

Meningococcal disease occurs as a result of invasive bacterial infection with the organism Neisseria meningitidis.

Meningococcal disease cases overwhelmingly show symptoms of meningitis (inflammation of the meninges) or septicaemia (blood poisoning).

Meningococcal disease is a significant cause of morbidity and mortality in children and young adults.

N. meningitidis is classified according to its outer membrane characteristics via a process known as serogrouping. There are a number of different serogroups, the most common of which in the UK is B followed by W. Cases of serogroup Y, Z and C disease have also been also reported. Currently there are vaccines to protect against certain strains within serogrouups A, B, C, W and Y.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of meningococcal disease and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

All data returned from ECOSS are used for analysis.

Scottish data is regularly compared to UKHSA meningococcal disease data and information.

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of new menigococcal infections.

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on laboratory-confirmed cases of mumps reported in Scotland for the period from July to September 2024 (week 39)

Infections in Scotland

Mumps infection

HTML

ECOSS (Electronic Communication of Surveillance in Scotland).

National Records of Scotland for mid-year population estimates (used for incidence calculations).

29 October 2024.

Agreed date to allow quality assurance checks.

3 December 2024

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 2000 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

Incidence rates in Table 2b in ‘Vaccine-preventable disease summary’ will differ slightly from previous publications for 2023 as these have been updated using the NRS mid-year population estimates for 2023.

Mumps is a disease resulting from infection by the mumps virus.

The disease is characterised by swelling of one or both cheeks or sides of the jaw, also known as parotitis, along with fever, headache and swollen glands although asymptomatic mumps infection is common, particularly in children.

Mumps is rarely fatal.

New cases of mumps included in the report are identified by laboratory testing based on positive PCR or IgM serology.

It is important to note that mumps may be diagnosed clnically and only laboratory-confirmed cases are included in the report.

Therefore the data presented may represent an underestimate of the true community circulation of mumps

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of mumps and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

All data returned from ECOSS are used for analysis.

Scottish data is regularly compared to UKHSA mumps data and information.

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of new mumps infections.

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024 

Immunisation and vaccine-preventable diseases quarterly report.

This report provides epidemiological information on positive laboratory cases of Bordetella pertussis in Scotland for the period July to September 2024 (week 39).

Infections in Scotland

Whooping cough

HTML

Electronic Communication of Surveillance in Scotland (ECOSS) for laboratory reports.

National Records of Scotland for mid-year population estimates (used for incidence calculations).

4 November 2024

Agreed date to allow quality assurance checks.

3 December 2024

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 2012 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

Incidence rates in Table 2b in ‘Vaccine-preventable disease summary’ will differ slightly from previous publications for 2023 as these have been updated using the NRS mid-year population estimates for 2023.

Whooping cough (or pertussis) is a highly contagious respiratory illness caused by infection with the bacterium Bordetella pertussis.

Pertussis is spread from person to person by coughing and sneezing.

Early symptoms often include a runny nose, fever, and mild cough, which after a few weeks can progress to uncontrolled coughing fits and subsequent vomiting episodes.

Some individuals with pertussis exhibit a characteristic "whoop" sound caused by gasping for breath after coughing fits.

Unimmunised infants are most at risk of severe complications, which include pneumonia, seizures, brain damage, and death.

Vaccination against pertussis is offered to infants at 8, 12, and 16 weeks of age and to children at 3 years and 4 months of age. Vaccination is also offered to all pregnant women between 16 and 32 weeks of gestation.

These data are essential for monitoring the epidemiology of pertussis and the uptake of the maternal pertussis vaccine in Scotland in order to inform public health planning and response.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

Count of pertussis laboratory reports (number).

Incidence of laboratory reports (rate per 100,000 population).

Age breakdown of laboratory reports (percentage).

Scottish data is regularly compared to UKHSA pertussis data and information.

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Count of pertussis laboratory reports (number).

Incidence of laboratory reports (rate per 100,000 population).

Age breakdown of laboratory reports (percentage).

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

9 August 2024 

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on poliomyelitis infections in Scotland for the period July to September 2024 (week 39).

Infections in Scotland

Poliomyelitis

HTML

ECOSS (Electronic Communication of Surveillance in Scotland).

15 October 2024

Agreed date to allow quality assurance checks.

3 December 2024

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data in the most recent quarterly updates supersedes data reported in previous reports.

This publication has no revisions.

Poliomyelitis (polio) is an acute viral illness caused by one of the three serotypes of poliovirus.

Most infections cause no symptoms, but in a small number of people can result in a potentially life-threatening infection that can cause temporary or permanent paralysis.

People may become infected with the polio virus through contact with infected faecal matter or respiratory secretions.

Immunisation against polio is offered to babies and children as part of the routine childhood immunisation schedule.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of poliomyelitis and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

All data returned from ECOSS are used for analysis.

Scottish data is regularly compared to UKHSA poliomyelitis data and information. 

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of laboratory-confirmed poliovirus infections.

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024 

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on laboratory-confirmed cases of invasive pneumococcal disease reported in Scotland for the period July to September 2024 (week 39).

Infections in Scotland

Pneumococcal disease

HTML

ECOSS (Electronic Communication of Surveillance in Scotland), Scottish Pneumococcal Invasive Disease Enhanced Reporting (SPIDER) surveillance scheme.

National Records of Scotland for mid-year population estimates (used for incidence calculations).

14 October 2024

Agreed date to allow quality assurance checks.

3 December 2024 

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 2004 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

Incidence rates in Table 2b in ‘Vaccine-preventable disease summary’ will differ slightly from previous publications for 2023 as these have been updated using the NRS mid-year population estimates for 2023.

Streptococcus pneumoniae (S. pneumoniae) is the bacterium responsible for causing pneumococcal infection.

Pneumococcal infections are defined as invasive or non-invasive according to which area of the body is affected.

Invasive pneumococcal disease (IPD) is caused by infection of normally sterile sites, for example, blood and cerebrospinal fluid (CSF). IPD is a major cause of morbidity and mortality in the very young, elderly or immunocompromised individuals. Two pneumococcal vaccines are available that help to protect against pneumococcal disease.

New cases of IPD are identified by laboratory reports confirming isolation of S. pneumoniae from sterile body sites.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of meningococcal disease and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

All data returned from ECOSS systems and the enhanced surveillance database are used for analysis.

Scottish data is regularly compared to UKHSA pneumococcal data and information.

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of new S. pnuemoniae isolates from sterile sites.

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on laboratory-confirmed cases of rotavirus for the period July to September 2024 (week 39).

Infections in Scotland

Rotavirus

HTML

Electronic Communication of Surveillance in Scotland (ECOSS) for laboratory reports.

National Records of Scotland for mid-year population estimates (used for rate calculations).

14 October 2024

Agreed date to allow quality assurance checks.

3 December 2024 

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 2011 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

Rotavirus case numbers and incidence in Tables 2a and 2b in ‘Vaccine-preventable disease summary’ have been amended for 2019 to 22 due to a transposition error in previous publications.   

Incidence rates in Table 2b in ‘Vaccine-preventable disease summary’ will differ slightly from previous publications for 2023 as these have been updated using the NRS mid-year population estimates for 2023.

Rotavirus infections in children and adults can last approximately three to eight days and symptoms include severe diarrhoea, vomiting, stomach cramps, mild fever.

The combination of symptoms can lead to dehydration, requiring admission to hospital, especially in young infants.

Before the introduction of a national infant rotavirus vaccination programme in 2013, an estimated 55,000 gastroenteritis cases caused by rotavirus occurred in Scotland each year in children less than five years old. Approximately 1,200 of these children were hospitalised.

The vaccine provides protection against the most common strains of rotavirus, but not other enteric viruses such as norovirus.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of rotavirus and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

All data returned from ECOSS are used for analysis.

Scottish data is regularly compared to UKHSA rotavirus data and information.

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Count of laboratory-confirmed rotavirus (number).

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024 

Immunisation and vaccine-preventable diseases quarterly report.

This release provides information on laboratory-confirmed and epidemiologically linked cases of rubella reported in Scotland for the period July to September 2024 (week 39).

Infections in Scotland

Rubella infection

HTML

ECOSS (Electronic Communication of Surveillance in Scotland), Colindale/UKHSA, enhanced surveillance database.

15 October 2024

Agreed date to allow quality assurance checks.

3 December 2024 

Quarterly

July to September 2024, approximately 2 months in arrears.

Quarterly as at March, June, September and December.

Data from 1988 to September 2024 (week 39) are presented.

Data in the most recent quarterly updates supersedes data reported in previous reports.

This publication has no revisions.

Rubella is a rash illness caused by the rubella virus and is also known as German measles.

It is generally a mild self-limiting illness, but if acquired by women in the first 16 weeks of pregnancy can have devastating effects on the unborn child inlcuding miscarriage or Congenital Rubella Syndrome (CRS).

New cases of rubella are identified by laboratory testing based on positive PCR or IgM serology.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of rubella and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

All data returned from ECOSS and the enhanced surveillance database are used for analysis.

Scottish data is regularly compared to UKHSA rubella data and information.

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Number of new rubella infections.

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024

Immunisation and vaccine-preventable diseases quarterly report.

This report provides information on hospital admissions for shingles and shingles related complications in Scotland which are proxy measures for shingles disease.

Infections in Scotland

Herpes zoster infection

HTML

Scottish Morbidity Record (SMR01) for hospital admissions for shingles and related complications.

National Records of Scotland for mid-year population estimates (used for rate calculations).

30 October 2023

3 December 2024

Quarterly

Hospital admission data from 2010 to 2022.

Data on hospital admissions due to shingles and related complications are provided from 2010 to 2022.

Data in the most recent quarterly updates supersedes data reported in previous reports.

This publication has no revisions.

Shingles, also known as herpes zoster, is caused by reactivation of latent varicella zoster virus, which is the same virus that causes chickenpox.

Following initial infection, usually in childhood, the virus can lie inactive in the body’s nervous system.

Reactivation of the virus can take place later in life, when the immune system has been weakened by factors such as age, stress, illness, or immunosuppressant treatments.

Shingles is characterised by a painful skin rash and the primary complication of this illness is post-herpetic neuralgia, a neuropathic pain which can last for months of years after the rash has disappeared.

Data are collected as part of mandatory public health surveillance providing data to monitor the epidemiology of herpes zoster and inform public health planning and response.

Statistics are used by PHS for surveillance purposes and published for transparency.

The data are considered accurate.

Data are validated locally by partnerships.

We carry out further validation checks in consultation with NHS boards, as required.

The Code of Practice for Statistics has been followed to ensure a high standard of data value, trustworthiness and quality.

Hospital admission data is analysed once SMR01 completeness reaches at least 95%.

Scottish data is regularly compared to UKHSA shingles data and information. 

It is the policy of PHS to make its websites and products accessible according to our accessibility statement. Graphs and tables have been assessed against PHS accessibility standards.

Accessibility of the report and findings are of continuous consideration throughout the report development.

The report has been produced using the standard PHS publications template and is available as HTML web pages.

Hospital admissions for shingles and related complications (rate per 100,000 population).

Coverage of shingles vaccination (percentage).

Our protocol on statistical disclosure is followed.

Official Statistics

Not assessed.

3 September 2024

4 March 2025

17 March 2020

phs.immunisation@phs.scot

6 November 2024